0 Évaluations

ID

14798

Description

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor; ODM derived from: https://clinicaltrials.gov/show/NCT00754325

Lien

https://clinicaltrials.gov/show/NCT00754325

Mots-clés

  1. 28/04/2016 28/04/2016 -
Téléchargé le

28 avril 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :


    Aucun commentaire

    Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

    Eligibility Advanced Breast Cancer NCT00754325

    Eligibility Advanced Breast Cancer NCT00754325

    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693 (Inclusion)
    histologically confirmed hormone receptor positive (hr+) [(estrogen receptor (er+) and/or progesterone receptors(pgr+)] breast cancer according to immunohistochemistry (ihc)
    Description

    hormone receptor positive breast cancer

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1562029 (Hormone receptor positive malignant neoplasm of breast)
    SNOMED
    417181009
    measureable or evaluable-only disease
    Description

    measureable disease

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1513041 (Measurable Disease)
    human epidermal growth factor receptor 2+ (her2+) or her2- breast cancer
    Description

    epidermal growth factor receptor breast cancer

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1960925 (Epidermal growth factor receptor positive non-small cell lung cancer)
    SNOMED
    426964009
    males and females ≥18 years of age
    Description

    age

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0001779 (Age)
    SNOMED
    424144002
    LOINC
    LP28815-6
    females are post menopausal or surgically sterile
    Description

    post menopausal or surgically sterile

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0021359 (Infertility)
    SNOMED
    15296000
    UMLS CUI [2]
    C0232970 (Postmenopausal state)
    SNOMED
    76498008
    recurrent or progressive advanced breast cancer (locally-advanced or metastatic), that has progressed: (a) during or within 12 months after completion of adjuvant aromatase inhibitor (ai) treatment or (b) during ai treatment in advanced setting (metastatic therapy)
    Description

    recurrent or progressive advanced breast cancer

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0596224 (breast neoplasm/cancer diagnosis)
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251 (Exclusion Criteria)
    pregnant or breast feeding
    Description

    pregnant or breast feeding

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0549206 (Patient currently pregnant)
    SNOMED
    77386006
    LOINC
    LA14670-6
    UMLS CUI [2]
    C0006147 (Breast Feeding)
    SNOMED
    169741004
    LOINC
    LP420040-0
    >1 chemotherapy regimen for advanced disease
    Description

    chemotherapy regimen

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0392920 (Chemotherapy Regimen)
    SNOMED
    716872004
    pleural or pericardial effusion
    Description

    pleural or pericardial effusion

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0032227 (Pleural effusion disorder)
    UMLS CUI [2]
    C0031039 (Pericardial effusion)
    SNOMED
    373945007
    LOINC
    LP411655-6
    serious cardiac condition
    Description

    cardiac condition

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0018799 (Heart Diseases)
    SNOMED
    56265001

    Similar models

    Eligibility Advanced Breast Cancer NCT00754325

    Name
    Type
    Description | Question | Decode (Coded Value)
    Type de données
    Alias
    Item Group
    C1512693 (UMLS CUI)
    hormone receptor positive breast cancer
    Item
    histologically confirmed hormone receptor positive (hr+) [(estrogen receptor (er+) and/or progesterone receptors(pgr+)] breast cancer according to immunohistochemistry (ihc)
    boolean
    C1562029 (UMLS CUI [1])
    measureable disease
    Item
    measureable or evaluable-only disease
    boolean
    C1513041 (UMLS CUI [1])
    epidermal growth factor receptor breast cancer
    Item
    human epidermal growth factor receptor 2+ (her2+) or her2- breast cancer
    boolean
    C1960925 (UMLS CUI [1])
    age
    Item
    males and females ≥18 years of age
    boolean
    C0001779 (UMLS CUI [1])
    post menopausal or surgically sterile
    Item
    females are post menopausal or surgically sterile
    boolean
    C0021359 (UMLS CUI [1])
    C0232970 (UMLS CUI [2])
    recurrent or progressive advanced breast cancer
    Item
    recurrent or progressive advanced breast cancer (locally-advanced or metastatic), that has progressed: (a) during or within 12 months after completion of adjuvant aromatase inhibitor (ai) treatment or (b) during ai treatment in advanced setting (metastatic therapy)
    boolean
    C0596224 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    pregnant or breast feeding
    Item
    pregnant or breast feeding
    boolean
    C0549206 (UMLS CUI [1])
    C0006147 (UMLS CUI [2])
    chemotherapy regimen
    Item
    >1 chemotherapy regimen for advanced disease
    boolean
    C0392920 (UMLS CUI [1])
    pleural or pericardial effusion
    Item
    pleural or pericardial effusion
    boolean
    C0032227 (UMLS CUI [1])
    C0031039 (UMLS CUI [2])
    cardiac condition
    Item
    serious cardiac condition
    boolean
    C0018799 (UMLS CUI [1])

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial